Alnylam Pharmaceuticals, Inc.

- There is no mention of any current or planned fundraising through debt or equity in the Q1 2026 earnings call. - The company ended Q1 2026 with $3 billion in cash, cash equivalents, and marketable securities, up from $2.9 billion at the end of 2025, driven by strong operating performance. - Alnylam has reiterated its full-year financial guidance without indicating a need for additional capital raises. - The focus appears to be on sustaining growth through commercial execution and pipeline advancement rather than external fundraising at this time.

The provided transcript does not specifically mention current or future capital expenditures (capex), capital investments, or strategic investments. However, relevant clues include: - Continued investment in R&D with a 39% increase in non-GAAP R&D expenses, focusing on multiple Phase III clinical studies and early pipeline programs. - Increased SG&A expenses by 36%, driven by support for the AMVUTTRA ATTR cardiomyopathy launch and organizational scaling. - Success in launching products ex-U.S., indicating ongoing investments in international market expansion, pricing, and reimbursement activities. - Mention of exciting new collaborations aimed at driving TTR disease awareness and improving care pathways, suggestive of strategic partnerships but no explicit capex details. No explicit details on infrastructure capex or specific capital investments are provided in the call.

- Alnylam expects continued strong growth in TTR product sales, targeting $4.4 billion to $4.7 billion in full-year 2026 TTR product sales. - Q2 and subsequent quarters are anticipated to show significantly higher quarter-on-quarter revenue growth, driving momentum throughout 2026. - Net product revenues exceeded $1 billion in Q1 2026, reflecting 121% year-over-year growth and 4% growth over Q4 2025. - U.S. TTR revenues grew 9% versus Q4 and over 230% year-over-year, despite some Q1 shipping week headwinds. - Internationally, revenues declined in Q1 due to Germany pricing adjustments but grew 35% year-over-year, notably strong in Japan. - Increased first-line adoption of AMVUTTRA is expected to drive deeper and earlier utilization. - Expansion of the prescriber base is a key strategy to sustain durable growth. - Market mix shifts and new launches (e.g., AMVUTTRA ATTR cardiomyopathy) will contribute to incremental growth, with growth becoming net positive from Q2 onwards.

- Alnylam reiterated its 2026 financial guidance with confidence, expecting $4.4 billion to $4.7 billion in TTR product sales. - Non-GAAP operating income for Q1 2026 was $339 million, more than a 4x increase compared to the previous year, driven by strong top-line growth. - The company reported its third consecutive quarter of both GAAP and non-GAAP profitability. - Continued strong growth in AMVUTTRA and ATTR cardiomyopathy sales supports sustained revenue increases. - Gross margins expected to decline slightly over the year due to rising royalty rates on AMVUTTRA sales. - Investments in R&D and SG&A expenses are increasing to support clinical programs and commercial expansion. - Alnylam is focused on expanding the prescriber base and deepening first-line use to drive durable growth. - Overall, the firm is confident in profitable growth anchored by robust product uptake and pipeline advancements.

The transcript does not provide explicit details on current or expected orderbook or pending orders in numeric terms. However, relevant information related to demand, orders, and market dynamics includes: - Demand-driven growth was a primary factor in Q1 results, with some inventory benefits offset by pricing effects (Page 7). - Ordering patterns were affected by calendar dynamics (number of Wednesdays impacting shipments) causing a Q1 headwind (Page 7). - Sequential improvement in demand was observed from January (lowest) through February and March 2026 (Page 7). - Strong new patient market share established over 75% before the CM indication, with continued category growth (Page 11). - First-line treatment adoption is growing, with second-line use normalizing, reflecting evolving prescribing patterns (Page 6, 12). - Access expanded to nearly 90% overall and over 90% first-line access, supporting demand growth (Page 11). No specific figures on pending orders or orderbook disclosed.